Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > TREM2


Brief Information

Name:Triggering receptor expressed on myeloid cells 2
Target Synonym:TREM-2,Triggering receptor expressed on monocytes 2,PLOSL2,Trem2b,Trem2a,Trem2c,Triggering Receptor Expressed On Myeloid Cells 2a
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Anti-TREM2 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TREM2, His Tag (Cat. No. TR2-H52H5) with an affinity constant of 95.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).


Loaded Human TREM2, Fc Tag (Cat. No. TR2-H5254) on Protein A Biosensor, can bind Human APOE3, His Tag (Cat. No. APE-H5246) with an affinity constant of 66.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

Triggering receptor expressed on myeloid cells 2,TREM2,TREM-2


Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell surface receptor of the immunoglobulin superfamily. The TREM2 is found in various tissue macrophages, such as CNS microglia, bone osteoclasts, alveolar, peritoneal and intestinal macrophages. TREM2 is also present on cultured bone marrow-derived macrophages and monocyte-derived dendritic cells. Some research have identified a rare variant of TREM2 that is a risk factor for Alzheimer disease (AD), which is the most common form of late-onset dementia.The extracellular region of TREM2 contains a single immunoglobulin superfamily domain and binds polyanionic ligands, such as bacterial lipopolysaccharide (LPS) and phospholipids8. Upon ligand binding, TREM2 transmits intracellular signals through an adaptor, DAP12 (also known as TYRO protein tyrosine kinase-binding protein (TYROBP)), which is associated with the transmembrane region of TREM2 and which recruits the protein tyrosine kinase SYK through its cytosolic immunoreceptor tyrosine-based activation motifs (ITAMs). TREM2 is a pro-tumorigenic marker of tumor-infiltrating macrophages in mouse models and human tumors that can be targeted to curb tumor growth and improve the efficacy of checkpoint blockade therapy while remodeling the landscape of tumor-infiltrating macrophages.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AL-002 AL-002a; AL-002-a; AL-002 Phase 2 Clinical Abbvie Inc, Alector Inc Alzheimer Disease Details
Iluzanebart VGL-101; VGL 101 Phase 2 Clinical Amgen Inc Posterior Leukoencephalopathy Syndrome; Nerve Degeneration Details
DNL-919 DNL-919; TAK-920 Phase 1 Clinical Denali Therapeutics Inc Alzheimer Disease Details
VG-3927 VG-3927 Phase 1 Clinical Vigil Neuroscience Inc Alzheimer Disease Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken